Safe weight loss medication: what actually works?

Weight loss medication has moved from the margins of British general practice to the centre of mainstream primary care in under three years. The arrival of the GLP-1 receptor agonists semaglutide (Wegovy) and tirzepatide (Mounjaro) has fundamentally changed what a GP can realistically offer a patient with obesity, and the NHS has responded with phased access through tier 3 and tier 4 weight management services. For private patients, the same drugs are available through regulated online prescribing services, which now represent the largest growing segment of UK obesity care. The question for patients is no longer whether medication works, but which medication, at what stage, and with what safeguards.

Who qualifies for weight loss medication in the UK?

NICE eligibility criteria are strict and reflect the evidence base. For Wegovy (semaglutide 2.4 mg weekly), patients must have a BMI of 35 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, obstructive sleep apnoea or dyslipidaemia, or a BMI of 30 to 34.9 plus a comorbidity if referred through specialist services. Mounjaro (tirzepatide) has similar thresholds and is now approved for NHS use on a phased rollout. The NHS obesity guidance sets the overall framework, while NICE technology appraisal TA875 is the definitive reference for semaglutide eligibility.

BMI cut-offs and ethnic adjustment

UK guidance recognises that BMI underestimates cardiometabolic risk in South Asian, Chinese, Middle Eastern, Black African and Caribbean populations.

For these groups, the BMI thresholds are lowered by 2.5 units, so obesity is diagnosed at BMI 27.5 and severe obesity at 32.5.

Private online services regulated by the CQC and MHRA will apply these adjustments during consultation.

The four main options, compared plainly

British prescribers currently choose between four licensed weight-loss medicines. Each has a distinct mechanism, efficacy and side-effect profile.

Semaglutide (Wegovy)

A once-weekly GLP-1 receptor agonist injection. Average weight loss at 68 weeks in the STEP-1 trial was 14.9% of body weight versus 2.4% on placebo.

Typical UK titration starts at 0.25 mg weekly and escalates every 4 weeks to a 2.4 mg maintenance dose.

Common side effects are nausea, constipation or diarrhoea, usually most marked in the first month of each dose step.

Contraindications include personal or family history of medullary thyroid carcinoma and MEN2.

Tirzepatide (Mounjaro)

A dual GIP and GLP-1 receptor agonist, also injected weekly.

The SURMOUNT-1 trial reported a mean weight loss of 20.9% at the highest dose over 72 weeks, the most impressive result for a pharmacological intervention outside bariatric surgery.

Titration mirrors semaglutide but extends through 2.5, 5, 7.5, 10, 12.5 and 15 mg steps.

Tolerability is broadly similar to semaglutide with a slightly lower rate of severe nausea in direct comparisons.

Orlistat (Xenical and Alli)

The oldest licensed option in the UK, available as prescription-only Xenical 120 mg three times daily, generic orlistat, or the pharmacy-only lower-dose Alli 60 mg. Orlistat inhibits pancreatic lipase, blocking absorption of roughly 30% of dietary fat. Mean weight loss over 12 months is a more modest 3 to 5%, but the safety profile is well established and the drug is useful for patients who prefer oral treatment or who are ineligible for GLP-1 agonists. Gastrointestinal side effects are predictable and directly linked to dietary fat intake.

Liraglutide (Saxenda)

A daily GLP-1 injection, now largely superseded by semaglutide and tirzepatide for most indications because the efficacy is lower and the injection burden higher. Still used in specific circumstances, particularly where a shorter-acting drug is preferred.

What a safe prescribing consultation looks like

A proper UK weight-loss consultation, whether NHS or private online, should cover all of the following before any prescription is issued:

• Verified BMI calculated from measured height and current weight, not self-reported figures from 2019.
• Comorbidity review including blood pressure, HbA1c or fasting glucose, lipid profile, and assessment for sleep apnoea symptoms.
• Mental health screen including history of eating disorders, depression and suicidal ideation, because GLP-1 agonists have post-marketing reports of psychological effects.
• Medication review especially thyroid medication, insulin, sulphonylureas and oral contraceptives (absorption may be reduced during the first month of tirzepatide).
• Personal history of pancreatitis, gallstones, gastroparesis, or medullary thyroid cancer.
• Family planning: GLP-1 drugs should be stopped at least 2 months before planned conception; orlistat is also not recommended in pregnancy.
• Realistic goal-setting: an agreed target weight loss of 5 to 15%, reviewed at 3 and 6 months, with a clear stopping rule if insufficient response.

Red flags that should delay or prevent prescription

A regulated prescriber will decline or defer treatment in the presence of:

• Current or recent eating disorder (bulimia, anorexia, binge eating disorder in active phase)
• Pregnancy or active attempts to conceive
• Severe gastroparesis or active inflammatory bowel disease
• Pancreatitis within the past 12 months
• BMI below the licensed threshold
• Unexplained rapid weight loss already in progress

How to take GLP-1 drugs and avoid the worst side effects

Most side effects of semaglutide and tirzepatide are dose-dependent and time-limited.

The single most effective mitigation is strict adherence to the titration schedule; trying to jump from 1 mg to 2.4 mg of semaglutide early, for example, is the commonest cause of severe nausea and dehydration.

Practical tips from UK prescribers:

• Inject on the same day each week; rotate sites between abdomen, thigh and upper arm.
• Eat slowly, in smaller portions, and stop when full rather than when the plate is empty.
• Avoid high-fat, high-sugar meals during the first week of each dose step; these are the classic trigger for vomiting.
• Drink 1.5 to 2 litres of water daily; dehydration magnifies nausea and is a common reason for A&E attendance.
• Keep fibre intake steady to prevent constipation; use a bulk laxative such as ispaghula husk if needed.
• If nausea is severe, delay the next dose step by 2 to 4 weeks rather than stopping altogether.

Monitoring, response assessment and stopping rules

UK best practice is to review at 3 months and 6 months. A response of at least 5% weight loss at 3 months on a maintenance dose is usually required to continue, and a 10% or greater response by 12 months is a realistic target for most patients on GLP-1 therapy. Blood pressure, pulse and any gastrointestinal or psychological symptoms should be checked at each review. BNF guidance on semaglutide specifies continued prescribing only where weight loss targets are being met.

Discontinuation typically causes weight regain of 60 to 70% of the lost weight over 12 months, which reflects the biology of obesity as a chronic, relapsing condition rather than a failure of the drug. For this reason, UK prescribing is moving towards a long-term maintenance model, often with dose reduction to the lowest effective level once goal weight is achieved. Patients with comorbid diabetes often continue GLP-1 therapy indefinitely because the cardiovascular and glycaemic benefits are independent of weight maintenance.

The role of diet, exercise and psychological support

Medication is never a substitute for behavioural change; it is a tool that makes behavioural change achievable for people who have genuinely tried and failed without pharmacological support.

The most successful UK outcomes combine weekly injection with a Mediterranean-style diet, 150 minutes weekly of moderate activity, and structured support through an app-based or in-person programme.

NHS Digital Weight Management and Healthier You programmes offer free 12-week courses that integrate well with medication.

Resistance training matters particularly during rapid weight loss phases.

Up to a quarter of mass lost on GLP-1 therapy without exercise can be lean tissue, which accelerates regain when treatment stops.

Two sessions weekly of moderate resistance work preserve muscle and the resting metabolic rate that depends on it.

Practical next steps

If you meet the BMI and comorbidity thresholds, your realistic options in the UK are: ask your GP for referral to a tier 3 specialist weight management service for NHS-funded GLP-1 therapy; self-refer to a private online prescribing service for immediate access; or start with orlistat while awaiting NHS assessment. Browse the full weight management category to compare products and pricing. Whichever route you choose, the evidence is clear: long-term, supported medical treatment of obesity works, and it works best when it starts early, runs long enough to matter, and is backed by sensible eating, consistent movement and honest reviews with a qualified prescriber.

Frequently asked questions about UK weight loss medication

Will my weight come back if I stop the injections?

In published follow-up studies, patients who stopped semaglutide after 68 weeks regained about two-thirds of the lost weight within 12 months.

This is not a personal failing; it is the biology of obesity, a condition in which body-weight set points are defended by hormonal and neurological mechanisms.

The implication for UK prescribers is that GLP-1 therapy should be framed from day one as a long-term commitment, with periodic dose reviews but not routine discontinuation at an arbitrary timeline.

Think of it the way you would think of statin therapy for cholesterol: ongoing, with the benefit present only while the drug is taken.

Can I use Wegovy or Mounjaro alongside antidepressants, the contraceptive pill or blood pressure medication?

Mostly yes, but with specific cautions.

GLP-1 agonists slow gastric emptying, which may reduce absorption of oral contraceptives during the first 4 weeks of tirzepatide titration; the UK recommendation is an additional barrier method or a switch to a non-oral method during this period.

Blood pressure and lipid medication doses often need downward adjustment as weight loss progresses, so book a review after significant loss.

Combining GLP-1 drugs with insulin or sulphonylureas in diabetic patients increases hypoglycaemia risk and usually requires a reduction in those background agents at the start of titration.

What do I do if I miss an injection?

If you remember within 5 days, inject as soon as possible and continue on your original weekly schedule.

If more than 5 days have passed, skip the missed dose and take the next one on the normal day; do not double up.

A single missed week does not meaningfully reset tolerability, but after a gap of 3 weeks or more, most prescribers recommend restepping down by one dose level to re-establish tolerance before resuming the full maintenance dose.

Is it safe to drink alcohol on GLP-1 therapy?

Moderate alcohol is not contraindicated, but two practical considerations apply.

First, many patients report a reduced desire for alcohol on semaglutide and tirzepatide, a phenomenon now being studied for alcohol use disorder.

Second, binge drinking on an already nauseated and slow-emptying stomach frequently triggers severe vomiting, dehydration and, in a small number of cases, acute pancreatitis.

Sensible moderation, particularly during dose escalation, is the right approach.

What happens to loose skin after major weight loss?

Weight loss of 15% or more from a BMI above 35 typically leaves some loose skin, particularly on the abdomen, upper arms and thighs.

Skin elasticity varies with age, duration of previous obesity and genetic factors. Resistance training helps by rebuilding the underlying muscle contour.

Surgical body contouring through the NHS is restricted to cases of significant functional impairment; most patients considering cosmetic correction pursue this privately once weight has been stable for at least 12 to 18 months.